Abstract Objective Many different genetic variants of proprotein convertase subtilisin kexin 9 (PCSK9) are related to the serum levels of cholesterol and LDL cholesterol (LDL-C). The rs615563 variant of PCSK9 (a gain-of-function mutation) is associated with increased triglycerides and cholesterol levels, but its association with the incidence of diabetes is not well defined. This study aimed to investigate the relationship between the PCSK9 rs615563 variant with the incidence of type 2 diabetes. The data reported in this study are based on subsamples from a 5-year (2009–2014) cohort study of the adult population (590 subjects) aged 20 years and older. The rs615563 polymorphism was genotyped using polymerase chain reaction (PCR) followed by ...
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipid metabolism,...
SummaryBackgroundStatin treatment and variants in the gene encoding HMG-CoA reductase are associated...
Abstract Background Genetic and environment factors affect the occurrence and development of coronar...
Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions ...
Background Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with ...
Abstract Background PCSK9 rs505151 and rs11591147 polymorphisms are identified as gain- and loss-of-...
Background Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with ...
BACKGROUND: Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with...
Aims/hypothesis: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of ch...
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipid metabolism,...
SummaryBackgroundStatin treatment and variants in the gene encoding HMG-CoA reductase are associated...
Abstract Background Genetic and environment factors affect the occurrence and development of coronar...
Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions ...
Background Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with ...
Abstract Background PCSK9 rs505151 and rs11591147 polymorphisms are identified as gain- and loss-of-...
Background Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with ...
BACKGROUND: Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with...
Aims/hypothesis: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of ch...
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipid metabolism,...
SummaryBackgroundStatin treatment and variants in the gene encoding HMG-CoA reductase are associated...
Abstract Background Genetic and environment factors affect the occurrence and development of coronar...